<DOC>
	<DOC>NCT01758432</DOC>
	<brief_summary>The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.</brief_summary>
	<brief_title>Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests</brief_title>
	<detailed_description>A randomized, double-blind, vehicle-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenously administered PRT064445 after dosing to steady state with one of four direct/indirect fXa inhibitors in healthy volunteers</detailed_description>
	<criteria>Healthy men or women between the ages of 18 and 45 years old History (including family history) or symptoms of, or risk factors for bleeding History (including family history) of or risk factors for a hypercoagulable or thrombotic condition Absolute/relative contraindication to anticoagulation or treatment with specific anticoagulants History of major surgery, severe trauma or bone fracture within 3 months prior to dosing; or planned surgery within 1 month after dosing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Healthy volunteers</keyword>
</DOC>